Seed · Biotech · Copenhagen, Denmark · Founded 2019 · 18–31 employees
Biograil develops the BIONDD technology platform that transforms injectable biologics into oral capsules using a novel device contained in standard capsules. The device uses injection molding technology to deliver active substances directly into the gastrointestinal wall, circumventing traditional barriers. The company has secured significant partnerships with pharmaceutical giants Eli Lilly and CSL Behring, validating their breakthrough approach. They've raised over $28 million across multiple funding rounds and are advancing toward clinical trials with their oral delivery platform.
No open roles listed right now.